Literature DB >> 24752603

Anthropometric factors and risk of molecular breast cancer subtypes among postmenopausal Norwegian women.

Julie Horn1, Mirjam D K Alsaker, Signe Opdahl, Monica J Engstrøm, Steinar Tretli, Olav A Haugen, Anna M Bofin, Lars J Vatten, Bjørn Olav Asvold.   

Abstract

Adult height and body weight are positively associated with breast cancer risk after menopause, but few studies have investigated these factors according to molecular breast cancer subtype. A total of 18,562 postmenopausal Norwegian women who were born between 1886 and 1928 were followed up for breast cancer incidence from the time (between 1963 and 1975) height and weight were measured until 2008. Immunohistochemical and in situ hybridization techniques were used to subtype 734 incident breast cancer cases into Luminal A, Luminal B [human epidermal growth factor receptor 2 (HER2-)], Luminal B (HER2+), HER2 subtype, basal-like phenotype (BP) and five-negative phenotype (5NP). We used Cox regression analysis to assess adult height and body mass index (BMI) in relation to risk of these subtypes. We found a positive association of height with risk of Luminal A breast cancer (ptrend , 0.004), but there was no clear association of height with any other subtype. BMI was positively associated with risk of all luminal breast cancer subtypes, including Luminal A (ptrend , 0.002), Luminal B (HER2-) (ptrend , 0.02), Luminal B (HER2+) (ptrend , 0.06), and also for the HER2 subtype (ptrend , 0.04), but BMI was not associated with risk of the BP or 5NP subtypes. Nonetheless, statistical tests for heterogeneity did not provide evidence that associations of height and BMI differed across breast cancer subtypes. This study of breast cancer risk among postmenopausal women suggests that height is positively associated with risk of Luminal A breast cancer. BMI is positively associated with risk of all luminal subtypes and for the HER2 subtype.
© 2014 UICC.

Entities:  

Keywords:  BMI; breast cancer; height; molecular subtype

Mesh:

Substances:

Year:  2014        PMID: 24752603     DOI: 10.1002/ijc.28912

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Size at birth and risk of breast cancer: update from a prospective population-based study.

Authors:  Marie Søfteland Sandvei; Pagona Lagiou; Pål Richard Romundstad; Dimitrios Trichopoulos; Lars Johan Vatten
Journal:  Eur J Epidemiol       Date:  2015-05-31       Impact factor: 8.082

2.  Height and Body Size in Childhood, Adolescence, and Young Adulthood and Breast Cancer Risk According to Molecular Subtype in the Nurses' Health Studies.

Authors:  Erica T Warner; Rong Hu; Laura C Collins; Andrew H Beck; Stuart Schnitt; Bernard Rosner; A Heather Eliassen; Karin B Michels; Walter C Willett; Rulla M Tamimi
Journal:  Cancer Prev Res (Phila)       Date:  2016-09

3.  Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer.

Authors:  Lu Chen; Linda S Cook; Mei-Tzu C Tang; Peggy L Porter; Deirdre A Hill; Charles L Wiggins; Christopher I Li
Journal:  Breast Cancer Res Treat       Date:  2016-05-24       Impact factor: 4.872

4.  Body Mass Index with Tumor 18F-FDG Uptake Improves Risk Stratification in Patients with Breast Cancer.

Authors:  Seung Hyup Hyun; Hee Kyung Ahn; Joo Hee Lee; Joon Young Choi; Byung-Tae Kim; Yeon Hee Park; Young-Hyuck Im; Jeong Eon Lee; Seok Jin Nam; Kyung-Han Lee
Journal:  PLoS One       Date:  2016-10-31       Impact factor: 3.240

5.  Obesity and Breast Cancer Risk in Men: A National Case-Control Study in England and Wales.

Authors:  Anthony J Swerdlow; Cydney Bruce; Rosie Cooke; Penny Coulson; James Griffin; Alison Butlin; Beverley Smith; M Jill Swerdlow; Michael E Jones
Journal:  JNCI Cancer Spectr       Date:  2021-08-28

6.  Could Anthropometric and Lipid Parameters Reflect Susceptibility to Breast Cancer? Comparison of Newly Diagnosed Breast Cancer and Apparently Healthy Women

Authors:  H M K Akalanka; S Ekanayake; K Samarasinghe
Journal:  Asian Pac J Cancer Prev       Date:  2018-09-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.